- Home
- FLYE vs MTVA Comparison
FLYE vs MTVA Comparison
Compare FLYE & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- MTVA
- Stock Information
- Founded
- FLYE 2018
- MTVA 2014
- Country
- FLYE United States
- MTVA United States
- Employees
- FLYE N/A
- MTVA N/A
- Industry
- FLYE Aerospace
- MTVA
- Sector
- FLYE Industrials
- MTVA
- Exchange
- FLYE Nasdaq
- MTVA NYSE
- Market Cap
- FLYE 16.9M
- MTVA 16.8M
- IPO Year
- FLYE 2024
- MTVA N/A
- Fundamental
- Price
- FLYE $0.46
- MTVA $1.60
- Analyst Decision
- FLYE
- MTVA Strong Buy
- Analyst Count
- FLYE 0
- MTVA 1
- Target Price
- FLYE N/A
- MTVA $12.00
- AVG Volume (30 Days)
- FLYE 957.4K
- MTVA 23.0K
- Earning Date
- FLYE 02-19-2025
- MTVA 03-27-2025
- Dividend Yield
- FLYE N/A
- MTVA N/A
- EPS Growth
- FLYE N/A
- MTVA N/A
- EPS
- FLYE N/A
- MTVA N/A
- Revenue
- FLYE $28,547,111.00
- MTVA N/A
- Revenue This Year
- FLYE N/A
- MTVA N/A
- Revenue Next Year
- FLYE N/A
- MTVA N/A
- P/E Ratio
- FLYE N/A
- MTVA N/A
- Revenue Growth
- FLYE N/A
- MTVA N/A
- 52 Week Low
- FLYE $0.38
- MTVA $1.51
- 52 Week High
- FLYE $7.62
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- MTVA N/A
- Support Level
- FLYE N/A
- MTVA N/A
- Resistance Level
- FLYE N/A
- MTVA N/A
- Average True Range (ATR)
- FLYE 0.00
- MTVA 0.00
- MACD
- FLYE 0.00
- MTVA 0.00
- Stochastic Oscillator
- FLYE 0.00
- MTVA 0.00
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.